Colin John Meyer Sells 20,000 Shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Stock


Reata Pharmaceuticals, Inc. (NASDAQ:RETA) insider Colin John Meyer sold 20,000 shares of Reata Pharmaceuticals stock in a transaction dated Monday, June 14th. The stock was sold at an average price of $144.05, for a total transaction of $2,881,000.00. Following the transaction, the insider now owns 77,000 shares of the company’s stock, valued at approximately $11,091,850. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of NASDAQ RETA traded up $0.12 during midday trading on Wednesday, reaching $142.71. 18,655 shares of the stock were exchanged, compared to its average volume of 366,516. The stock has a market capitalization of $5.18 billion, a P/E ratio of -18.45 and a beta of 1.48. Reata Pharmaceuticals, Inc. has a 52-week low of $76.34 and a 52-week high of $186.82. The stock’s 50 day simple moving average is $107.67.

Reata Pharmaceuticals (NASDAQ:RETA) last issued its quarterly earnings results on Thursday, May 6th. The company reported ($1.86) EPS for the quarter, topping analysts’ consensus estimates of ($2.18) by $0.32. Reata Pharmaceuticals had a negative net margin of 3,092.54% and a negative return on equity of 88.44%. The business had revenue of $0.94 million during the quarter, compared to the consensus estimate of $1.43 million. During the same period in the previous year, the firm posted ($0.89) earnings per share. The company’s quarterly revenue was down 30.2% compared to the same quarter last year. Equities research analysts expect that Reata Pharmaceuticals, Inc. will post -8.26 EPS for the current year.

(Ad)

Watch his 32-second options trading “training video” here.

Institutional investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can grew its holdings in Reata Pharmaceuticals by 79.9% in the first quarter. Bank of Montreal Can now owns 545 shares of the company’s stock valued at $51,000 after purchasing an additional 242 shares during the period. First Mercantile Trust Co. grew its holdings in Reata Pharmaceuticals by 40.4% in the first quarter. First Mercantile Trust Co. now owns 660 shares of the company’s stock valued at $66,000 after purchasing an additional 190 shares during the period. Penserra Capital Management LLC purchased a new stake in Reata Pharmaceuticals in the fourth quarter valued at approximately $82,000. Panagora Asset Management Inc. purchased a new stake in Reata Pharmaceuticals in the first quarter valued at approximately $96,000. Finally, US Bancorp DE grew its holdings in Reata Pharmaceuticals by 41.2% in the fourth quarter. US Bancorp DE now owns 1,028 shares of the company’s stock valued at $127,000 after purchasing an additional 300 shares during the period. Hedge funds and other institutional investors own 69.02% of the company’s stock.

RETA has been the subject of a number of research reports. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell lifted their target price on shares of Reata Pharmaceuticals from $234.00 to $244.00 and gave the stock a “buy” rating in a research report on Thursday, May 20th. The Goldman Sachs Group initiated coverage on shares of Reata Pharmaceuticals in a research report on Monday, May 24th. They set a “buy” rating and a $236.00 target price for the company. Citigroup lifted their target price on shares of Reata Pharmaceuticals from $234.00 to $244.00 and gave the stock a “buy” rating in a research report on Thursday, May 20th. Finally, Barclays began coverage on shares of Reata Pharmaceuticals in a report on Monday, April 26th. They set an “overweight” rating and a $155.00 price target for the company. Six analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average target price of $224.38.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich’s ataxia; and conduct Phase II study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others.

Read More: Google Finance Portfolio Tips and Tricks

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: Short Selling – Explanation For Shorting Stocks

7 Things You Need To Know About Cryptocurrency

The Cryptocurrency Market Is About To Boil Over

The cryptocurrency was quiet for years, but it’s starting to boil over once again. With the price of Bitcoin up 550%, it certainly seems like the sky is the limit.

Whether or not you choose to trade Bitcoin or any other cryptocurrency, it is important to understand what it is and the trends driving it.

The bottom line, however, is that the world’s money is flowing onto the blockchain, and the use of cryptocurrency is growing at an exponential rate.

View the “7 Things You Need To Know About Cryptocurrency”.



Read More:Colin John Meyer Sells 20,000 Shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Stock

Leave a Reply

Your email address will not be published. Required fields are marked *